Literature DB >> 31819763

The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®).

Francesca Morgante1, Ganesh Bavikatte2, Fahim Anwar3, Biju Mohamed4.   

Abstract

Sialorrhoea is a frequent symptom of neurological diseases (e.g. Parkinson's disease, motor neuron disease, cerebral palsy, and stroke) and is defined as excessive saliva accumulation leading to unintentional loss of saliva from the mouth. Sialorrhoea increases the overall burden on the patient and their caregivers, the impact of which can be both physical and psychosocial. Treatments for sialorrhoea range from lifestyle and behavioural guidance, to medications, surgery or radiation. Nonpharmacological interventions include advice on posture, swallowing control, cough management, dietary changes, eating and drinking techniques, and behavioural modification; however, these conservative measures may be ineffective for people with progressive neurological conditions. The pharmacological treatment of sialorrhoea is challenging because medications licensed for this purpose are limited, but treatments can include anticholinergic drugs and botulinum toxins. Surgical treatment of sialorrhoea is typically reserved as a last resort for patients. IncobotulinumtoxinA (Xeomin®) is the first botulinum toxin type A to receive US and UK marketing authorization for the symptomatic treatment of chronic sialorrhoea due to neurological disorders in adults. In this review, we discuss and compare the frequency and method of administration, location of treatment delivery, approximate annual costs and main side effects of botulinum toxin and different anticholinergic drugs. Management of patients with chronic neurological conditions requires input from multiple specialist teams and thus a multidisciplinary team (MDT) approach is considered fundamental to ensure that care is consistent and tailored to patients' needs. To ensure that adult patients with neurological conditions receive the best care and sialorrhoea is well managed, we suggest a potential clinical care pathway for sialorrhoea with a MDT approach, which healthcare professionals could aspire to.
© The Author(s), 2019.

Entities:  

Keywords:  Motor; Parkinson’s disease; botulinum toxin; incobotulinumtoxinA; neuron disease; sialorrhoea

Year:  2019        PMID: 31819763      PMCID: PMC6883364          DOI: 10.1177/1756286419888601

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  5 in total

1.  The Prevalence and Management of Saliva Problems in Motor Neuron Disease: A 4-Year Analysis of the Scottish Motor Neuron Disease Register.

Authors:  Iona Pearson; Stella A Glasmacher; Judith Newton; Emily Beswick; Arpan R Mehta; Richard Davenport; Siddharthan Chandran; Suvankar Pal
Journal:  Neurodegener Dis       Date:  2021-04-26       Impact factor: 2.977

Review 2.  GSK-3β-mediated regulation of Nrf2/HO-1 signaling as a new therapeutic approach in the treatment of movement disorders.

Authors:  Divya Soni; Puneet Kumar
Journal:  Pharmacol Rep       Date:  2022-07-26       Impact factor: 3.919

Review 3.  Sialorrhea in Parkinson's Disease.

Authors:  Jonathan Isaacson; Sanskruti Patel; Yasar Torres-Yaghi; Fernando Pagán
Journal:  Toxins (Basel)       Date:  2020-10-31       Impact factor: 4.546

4.  Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI.

Authors:  Steffen Berweck; Marcin Bonikowski; Heakyung Kim; Michael Althaus; Birgit Flatau-Baqué; Daniela Mueller; Marta Dagmara Banach
Journal:  Neurology       Date:  2021-08-02       Impact factor: 11.800

Review 5.  Oral Health Disorders in Parkinson's Disease: More than Meets the Eye.

Authors:  Manon Auffret; Vincent Meuric; Emile Boyer; Martine Bonnaure-Mallet; Marc Vérin
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.